Skip to main content
main-content

05.05.2016 | Brief Report | Ausgabe 2/2016 Open Access

Diabetes Therapy 2/2016

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment

Zeitschrift:
Diabetes Therapy > Ausgabe 2/2016
Autoren:
Thomas Blevins, James Ruggles, Elise Hardy
Wichtige Hinweise

Enhanced content

To view enhanced content for this article go to http://​www.​medengine.​com/​Redeem/​73C4F06070F9D834​.

Abstract

Introduction

Exenatide is gradually released from exenatide once weekly (QW) microspheres, and at steady state, consistently controls glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2D). This post hoc analysis examined the timing to onset of clinical responses and their correlations with exenatide concentrations after initiation of exenatide QW in patients with T2D.

Methods

Trial data were retrospectively analyzed to explore the early clinical responses to exenatide QW, including the relationship of exenatide concentration with its effects on efficacy [fasting plasma glucose (FPG), HbA1c, and body weight] and tolerability (nausea and vomiting). Exenatide QW efficacy and tolerability data were from DURATION-5, a 24-week, randomized, comparator-controlled trial [intent-to-treat (ITT) population]. Exenatide concentrations were measured in a patient subset (pharmacokinetic population).

Results

In the ITT (n = 129)/pharmacokinetic (n = 72) populations, baseline FPG, HbA1c, and body weight were 173/173 mg/dL, 8.5%/8.4%, and 97/98 kg, respectively. Exenatide concentrations gradually increased until reaching steady state at week 8. By week 4, the FPG reduction (−32.4 mg/dL) was 94% of the week 24 reduction (−34.6 mg/dL). Reductions in HbA1c began by week 4 (−0.6%) and stabilized by week 14 (week 24: −1.6%). Weight reduction at week 4 was −0.7 kg and decreased further (week 24: −2.3 kg). Peak nausea (7.2%) and vomiting (2.4%) occurred at weeks 6–8, declining thereafter.

Conclusion

Clinically relevant responses to exenatide QW were evident by week 4, after exenatide concentration passed the therapeutic threshold but before steady state was achieved.

Trial Registration

ClinicalTrials.gov identifier: NCT00877890.

Funding

AstraZeneca.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2016

Diabetes Therapy 2/2016 Zur Ausgabe